1 2

Size: px
Start display at page:

Download "1 2"

Transcription

1

2 1 2

3 1

4 1pH WPC-Type25WPH-Type25F-Type N-Type

5 a b

6 31997b

7 4 41

8 32008

9

10 5

11 4Uchino et al.,

12

13 5 6 LDH IgE Uchino et al., 2003 LDH AD

14 5 AD NC/Nga 8 IgE Matsuda et al., 1997 NCN24 NC/Nga NC/Nga Takada et al.,

15 6 NC/Nga IgE Ichihashi et al., 2003 NC/Ng

16 5 NC/Nga IgE MT-I, MT-II 6

17 7 A B

18

19

2009 Aida et al. Caries Res 2006;40 2000 100 % 78.7 88.0 96.6 98.8 98.8 98.8 100.0 100.0 100 75 69.4 50 75.3 74.8 73.3 73.1 73.0 72.4 71.8 71.7 51.7 40.2 69.4 68.8 73.6 25 22.3 32.8 21.9 22.9 22.1

More information

P15 P211 1 P1 P4 P2 P3 P4 P17

P15 P211 1 P1 P4 P2 P3 P4 P17 P15 P211 1 P1 P4 P2 P3 P4 P17 P3 P4 P7 P8 P9 2 1 Q A P17 P17 1 2 3 4 3 5 6 7 8 2 P17 Q A P17 4 1 2 3 4 2 P17 P4 P12 P17 P4 5 5 6 7 8 2 P4 P4 6 1 2 3 4 3 P17 P10 P17 7 5 6 7 8 4 0120-096-991 P17 8 1 2 3

More information

産衛誌57-4たより.indb

産衛誌57-4たより.indb A89 26 7 1 9 4 33 1 87 A90 24 A91 23 ACOH2014 A92 4 1 2 3 4 5 6 7 A93 A94 A95 A96 A97 A98 A99 A100 A101 27 8 1 9 A102 4 33 A103 A104 26 3 140 27 1 A105 27 A106 A107 A108 A109 A110 A111 A112 A113 et al

More information

3 JAS JAS JAS 4

3 JAS JAS JAS 4 1 2 3 JAS JAS JAS 4 5 6 7 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 ph 102 106 K 31 32 13 3 15 79 33 34 35 36 37 20 6 H.22.3 http://www.caa.go.jp/foods/pdf/syokuhin19.pdf 38

More information

2.2 (1967) (1997,2003) 2.2 ( ) 11

2.2 (1967) (1997,2003) 2.2 ( ) 11 ( ) 2.1 10 2.2 (1967) (1997,2003) 2.2 ( ) 11 12 ( ) 90150 (684) (887) (1099) (1361) (1605) (1707) (1854) 21(1946) 8 2.3 (1854) 13 (1997) (1854.12.23) (M8.4) (24 ) (M8.4) 70,000 3000 ( ) 7 2 3 3 (,1997)

More information

0.02ml IgE RAST MAST CAP 2

0.02ml IgE RAST MAST CAP 2 ( ) 1 0.02ml IgE RAST MAST CAP 2 3 1963 30 4 1986 20 39 IgE 30% 1988 54.7% IgE 47.6% 1990 892 IgE 27% 12% 1995 2379 1995 8 15 1996 1 12 2335 98.5% 2335 24 61 47 44.0 1 1) 2335 613 26.3% 2 5 613 43.4 44.2

More information

( ) ー ( () ) 250 200 150 100 50 0 51 20 54 59 33 35 91 92 93 98 99 94 6 7 7 8 9 11 18 17 18 20 22 23 10 9 8 9 9 9 62 40 66 74 41 47 21 22 23 24 25 26 10 8 6 4 2 0 m3/s 7 41.3 5 5 18.4

More information

日本目録規則1987年版改訂2版第2章図書改定案

日本目録規則1987年版改訂2版第2章図書改定案 2.0.1 2.0.2 2.0.3 2.0.4 2.0.5 2.0.6 2.1.1 2.1.2 2.1.3 2.1.4 2.1.5 2.2.1 2.2.2 2.2.3 2.2.4 2.4.1 2.4.2 2.4.3 2.4.4 2.5.1 2.5.2 2.5.3 2.5.4 2.6.1 2.6.2 2.6.3 2.6.4 2.6.5 ISSN 2.6.6 2.6.7 2.7.1 2.7.2 2.7.3

More information

70% ADCA 28% SCA6 30% MJD 30% DRPLA 13% 20% SCA1 4% SCA2 3% RCA 2% 537 25 T2 C3 C6) LCL MRI OB ph3 ph9 60/40/20mg/ 1000mg/ 3 500mg/ 6 1000mg/ 3 6/ 2 1 2 3 50 25 0 75 100 % 100 33 67 75 80

More information

MI( MI() 100% 100% 75% 75% 33% 75% 60% 40% 25% 60% 1 2 3 4 5 6 7 8 9 () 12 () () () !! 1. 2. 3. 1. 2. () () () 3-5% ex. ex. 11 ex. () ex. ex. : ex. : (insula) () () ( 2009 ) () ( ) YES! ()

More information

untitled

untitled NO.50 2009 10 10 0570-058-669 http://www.i-nouryoku.com/index.html 35 45 1 29 () 40 1 NO.50 2009 10 ha1.5ha 1.5haha1.5ha 1.5haha 10ha ha [] 150 2 NO.50 2009 10 [] a [] 1.5ha 3 NO.50 2009 10 4 NO.50 2009

More information

新たな基礎年金制度の構築に向けて

新たな基礎年金制度の構築に向けて [ ] 1 1 4 60 1 ( 1 ) 1 1 1 4 1 1 1 1 1 4 1 2 1 1 1 ( ) 2 1 1 1 1 1 1 1996 1 3 4.3(2) 1997 1 65 1 1 2 1/3 ( )2/3 1 1/3 ( ) 1 1 2 3 2 4 6 2.1 1 2 1 ( ) 13 1 1 1 1 2 2 ( ) ( ) 1 ( ) 60 1 1 2.2 (1) (3) ( 9

More information

無印良品 キッチン・テーブル クリーニング・バス用品 2010春夏

無印良品 キッチン・テーブル クリーニング・バス用品 2010春夏 200 6 6 7 8 2 4 6 6 7 7 7 2 8 8 9 9 9 20 20 2 22 22 22 24 24 24 25 26 26 28 28 29 29 30 30 3 www.muji.net 32 32 33 34 34 859275 35 39 4 42 35 36 35 37 36 38 39 40 40 40 4 4 42 44 43 45 46 47 47 48 49 50

More information

無印良品 キッチン・テーブル・クリーニング・バス用品 2009 春夏

無印良品 キッチン・テーブル・クリーニング・バス用品 2009 春夏 2009 2009 6 6 8 2 4 6 8 8 9 9 9 2 20 20 2 2 2 22 22 22 23 24 25 25 23 26 26 27 27 28 30 30 3 3 32 32 32 www.muji.net 34 34 35 35 35 36 36 37 37 37 38 39 854845 42 43 44 48 38 4 42 42 42 43 43 45 47 46

More information

がん患者の終末期ケアにおける通所リハビリテーションの役割 介護保険によるがん終末期ケアの可能性

がん患者の終末期ケアにおける通所リハビリテーションの役割 介護保険によるがん終末期ケアの可能性 2 3 3 6 7 49 53 13 61 22 27 65 68 34 47 71 73 4 5 7 6 8 9 10 11 12 13 14 15 44 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4

More information

3 4 6 7 8 9 10 12 14 2 3

3 4 6 7 8 9 10 12 14 2 3 3 4 6 7 8 9 10 12 14 2 3 POINT 4 5 3053 1323 4 7 6 1 1 4 7 Yamada N. et al : Int J Cardiol. 98, 409-411, 2005 6 7 POINT 0 20 40 60 80 100 60 80 Ota M. et al: Heart Vessels. 17, 7-11,2002 40 60 20 50 15

More information

2

2 C o r n e l i u s The Science of E m o t i o n I z a r d The Psychology of Emotions Rusalova et al. Schwartz et al E M G 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 The science of emotion The psychology

More information

NIHSS score p NIHSS score p149 4 p g ml 0.8 g ml D 1 D NIH NIHSS 14 D 0.8 g ml

NIHSS score p NIHSS score p149 4 p g ml 0.8 g ml D 1 D NIH NIHSS 14 D 0.8 g ml NIHSS score14 1 400 1 p149 1 25 20 NIHSS score14 15 10 5 2 p149 4 p151 0 0.8 g ml 0.8 g ml D 1 D NIH NIHSS 14 D 0.8 g ml 1 2 148 149 3 2 3 A B C 4 D 2 A B C A C 1 Ogata T et al J Neurol Sci 272 83 86 2008

More information

21 1 1 1 2 2 5 7 9 11 13 13 14 18 18 20 28 28 29 31 31 34 35 35 36 37 37 38 39 40 56 66 74 89 99 - ------ ------ -------------- ---------------- 1 10 2-2 8 5 26 ( ) 15 3 4 19 62 2,000 26 26 5 3 30 1 13

More information

喘息について\(公健協会宛02-5作成\)

喘息について\(公健協会宛02-5作成\) Q & A Q & A 1.? 20 2. 1) 2) 3) 4) 5) 6) 7) 1) 2) 3) 4) 5) 6) 7) 8) 9) 3. NHK ( ) 4 10 1 200mg ( ) ( 1 ) 4. ( ) ( ) 5. ( ) ( ) 6. β 2 ( ) 7. ( ) 1 8. 1. 2. 3. 4. 5. 6. 7. 8. 9. 2 5 7 1. 1 10 1) 2) 3) 30

More information

437“ƒ

437“ƒ et al., et al., et al., et al., et al., et al., 2 et al., et al., et al., Lancet Pharmacol Res. et al. Jpn J Cancer Res. et al. Jpn J Cancer Res. et al. Tohoku J Exp Med. et al. Jpn Circ J. et al. Cancer

More information

07-第4章村上英吾.indd

07-第4章村上英吾.indd 1990 1990 2007 2000 2007 9 3 46 1 2 1960 1 1984 60 3 1970 4 2000 2003 2009 2011 12007 2 2007 12 25 2 1 2007 10 19 1 5 2007 12 11 3 Bradshaw, J., et. al., 2008. 41982 47 2010 5 2011 2004 2004 1994 5 2009

More information

感染症学雑誌第77巻第8号

感染症学雑誌第77巻第8号 1 2 µ Streptococcus pneumoniae µ S. pneumoniae µ S. pneumoniae pbp β β pbp1a pbp2x pbp2b pbp mefe ermb pbp pbp1a pbp2x pbp2b pbp pbp pbp pbp 2x pbp1a pbp2x pbp 2b mefe ermb pbp β pbp2x β β β µ µ pbp3 µ

More information

スライド 1

スライド 1 e-japan -2004 1 Integrated Healthcare Network (IHN) e-icusentara Sentara Healthcare T C I H A H I 0 5 0 3 T C I H A H I 2 10 6 1 0 1935 40 45 50 55 60 65 70 75 80 85 90 95 2000 K. Matsuoka et al.

More information

: : 2001227 : 2

: : 2001227 : 2 : : 2001227 : 2 mg/100gmg/100g mg/100g 3 10/102006 12/05 2/19, 2007 Zn 63 98 4 10% 5 Ramesh et al. 2004 6 Connoly et al. 2002 A IRT 7 8 2.11mg/100g143%56% 9 10 Alaria praelonga 11 2 12 13 14 15 16 1 1

More information

2

2 1 2 3 4 5 6 7 8 9 10 11 12 13 14 10mSv 15 16 17 4.46 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 3.8 2.07 2.91 1.37 2.3 1.31 1.84 1.56 1.2 1.33 2.03 0.5 1000 4000mSv 1000 4000mSv Preston et al. Radiat Res 168: 1 64,

More information

2 129-B*-006P 129-B*-007P C*-004P 129-D*-001P ADH B*-006P B*-007P C*-004P D*-001P Na

2 129-B*-006P 129-B*-007P C*-004P 129-D*-001P ADH B*-006P B*-007P C*-004P D*-001P Na 2.7.4 2.7.4.1 2.7.4.1.1 11 ADH 1 ADH 1 4 7 129-A*-003 129-B*-001 129-E*-001P 129-G*-001 129-H*-002 129-H*-004 129-H*-005 132 242 4 129-B*-004 129-C*-005P 129-H*-003 129-H*-006 44 ADH ADH 129-C*-001P 16

More information

28_04_斎藤正章.indd

28_04_斎藤正章.indd 37 2820103743,. 282010.3743 純 粋 持 株 会 社 における 経 営 管 理 上 の 課 題 1 2 ABSTR ACT...... 1 2 1 38 2 1 1 3 2 1 1 4 5 6 7 8 1 2 1 1992.269 39 1 1 1 2 9 1 2 3 123 13 2 1995.268 40,.1995 3 10, et al.1995 2 1950 2

More information

Taro10-名張1審無罪判決.PDF

Taro10-名張1審無罪判決.PDF -------------------------------------------------------------------------------- -------------------------------------------------------------------------------- -1- 39 12 23 36 4 11 36 47 15 5 13 14318-2-

More information

会津若松市民の運動行動における変化ステージの評価

会津若松市民の運動行動における変化ステージの評価 2 Bandura1977 2000 Bandura 50 36 3 4 MarcusSimkin1993 2002 6 6 6 6 1995 2000.81 1998 1995 2000.91 2000 5 .65 1986.83 Marcus et al1992 2002 Pros.81 Cons.80 Pros Cons Pros Cons 6 7 8 9 10 11 12 13 5 Tukey

More information

1. - - - 2 - - 3 - - 4 - 1 Muser KT, Bond GR, Drake RE, et al(1998). Model of community care for severe mental illness: A review of research on case management. Schizophrenia Bulletin, 24(1): 33-74. -

More information

yokotoriforPDF

yokotoriforPDF 2014 1 5/18 3 7/6 2 6/15 5 8/48/7 AD 4 7/22 AD 1316510 2014 846 23 5/186/157/6 7/228/48/118/12 10:1512:15 8/712:0018:00 8/188/19 8/248/25 9:1514:15 2 9/79/149/21 10/1910:1512:15 8F 1 5/18? 16 2 6/15 2014

More information

取扱説明書

取扱説明書 B6FJ-7351-01 LIFEBOOK PH .................................................... 5.................................................................. 8....................................................................

More information

2 章 +αの 情 報 に 着 目 する! 1 血 球 算 定 検 査 結 果 2 生 化 学 検 査 結 果 手 がかりに 乏 しいのも+α 1 症 例 をみてみよう! 1 60 吉 見 祐 輔 1 2 11percutaneous coronary intervention PCI104 38.

2 章 +αの 情 報 に 着 目 する! 1 血 球 算 定 検 査 結 果 2 生 化 学 検 査 結 果 手 がかりに 乏 しいのも+α 1 症 例 をみてみよう! 1 60 吉 見 祐 輔 1 2 11percutaneous coronary intervention PCI104 38. 2 章 +αの 情 報 に 着 目 する! 1 血 球 算 定 検 査 結 果 2 生 化 学 検 査 結 果 手 がかりに 乏 しいのも+α 1 症 例 をみてみよう! 1 60 吉 見 祐 輔 1 2 11percutaneous coronary intervention PCI104 38.1 130 75mmHg 83 16 SpO 297 1 3 WBCL RBC10 4 L Hb g

More information

2002.N.x.h.L.......g9/20

2002.N.x.h.L.......g9/20 1 2 3 4 5 6 1 2 3 4 5 8 9 1 11 11 12 13 k 14 l 16 m 17 n 18 o 19 k 2 l 2 m 21 n 21 o 22 p 23 q 23 r 24 24 25 26 27 28 k 28 l 29 m 29 3 31 34 42 44 1, 8, 6, 4, 2, 1,2 1, 8 6 4 2 1, 8, 6, 4, 2, 1,2 1, 8

More information

20●12頁●6-14▲放射線科▲.ppt

20●12頁●6-14▲放射線科▲.ppt No.268 Katayama H. et al. Adverse reactions to ionic and nonionic contrast media-a report from the Japanese Committee of the Safety of Contrast Media. Radiology 1990;175:621-628. 12.66% 3.13% 0.22% 0.04%

More information

Microsoft Word - 世界史 第77講〜第79講 テキスト.docx

Microsoft Word - 世界史 第77講〜第79講 テキスト.docx 1853 (1854 ) (1858 ) (1868 ) (1) (1871 ) (1874 ) (1879 ) (1875 ) (2) (1889 )(1890 ) 1 19 ( 18631907 ) ( )(1875 ) (1876 ) 3 () () (1885 ) () 琫 2 (1895 ) 3 4 1863 A 26 A B B B A A C 11875 76 2 C 1881 2 1882

More information

/ B B ( ) ( -298) VL VH( ) Very Low( ) Very High( ) ( 10 2 %) (g/l) ( 10 2 %) 0.75 ( 10 2 %) 0.15 ( 10 2 %)

/ B B ( ) ( -298) VL VH( ) Very Low( ) Very High( ) ( 10 2 %) (g/l) ( 10 2 %) 0.75 ( 10 2 %) 0.15 ( 10 2 %) / B B ( ) ( -298) VL VH( ) Very Low( ) Very High( ) (10 2 %) 0.32 0.55 0.37 0.55 95 165 115 185 (10 2 %) 0.75 (10 2 %) 0.15 (10 2 %) 0.10 10 2 % 0.10 10 2 % 0.15 10 2 % 0.10 Bands(10 2 %) 0.10 (10 9 75

More information

13 13 13 13 M 1000 1001 1002 1003 1004 1005 12 54 67 12 133 5 14 1006 12 71 72 43 186 5 14 1007 1 1008 35-62-1 C 35--62-31 C 35-62-2 B 35-62-32 C 35-62-3 A 35-62-33 C 35-62-4 B 35-62-34 C 35-62-5 C 35-62-35

More information

200mg 2005 3 876179 2002 3 3 200mg VFEND for Intravenous Use (1) (2) [4.1 ] (3) [4.2 ] (1) [1] (2) (3) [1] 3

More information

untitled

untitled 80(4)70 80(4)70 852011 1 2 Cs Brown et al.,2008a 80(4)70 852011 3 H H C H H H C H H H C H O H O H O O O H H C H O O O H C O 4 2 + H 2 O HO + H + + pka=10.4 - HOCl HO/O- HOCl O - 3 - + O 3-5 131 1988 530200

More information

4) H. Takayama et al.: J. Med. Chem., 45, 1949 (2002). 5) H. Takayama et al.: J. Am. Chem. Soc., 112, 8635 (2000). 6) H. Takayama et al.: Tetrahedron Lett., 42, 2995 (2001). 9) M. Kitajima et al: Chem.

More information

ml DNA DNA

ml DNA DNA ml DNA DNA ml PH HO DNADNA DNA LED LED CD CD ch 概 概 mll IC LED OK CD CDDVD CD LED LED LED The LED PVA Part LED LED PPT V LED AI LED V AlCu Fe Al Al PVA ml 概 概 CD CD OHP etc cm PET cm PET cm PET LED LED

More information

UV UV UV UV UV UV UV UV

UV UV UV UV UV UV UV UV 2 UV UV UV UV UV UV UV UV UV Features Properties Characteristics Features Properties Z-700K-2 Z-700KAG-7 100 0 Z-700K-2 Z-700KAG-7 50 50 Z-700K-2 Z-700KAG-7 0 100 60 Characteristics AG(%) UV UV Features

More information

387 ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )

387 ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) 386 B B () () ( ) ( ) ( ) 387 ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) 388 ( ) ( ) ( ) 389 ( ) 2 ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) 390 ( ) ( ) ( ) () () ( ) Hot flush 391 ( ) ( ) ( ) 392 ( ( )

More information

13 3 21 11 60 11 3 10 13 3 21 11 3 10 38 11 7 23 1 11 11 12 39 12 2 29 2 12 3 15 40 12 8 30 3 12 11 2 41 13 2 20 4 13 3 15 42 13 3 15 10 14 16 1900 1945 1985 ( ) ( ) 1 2 6 2 Thiobacillus SO 2-4 H 2 S

More information

1 2 2/17

1 2 2/17 1/17 1 2 2/17 ROM ROM 2 CD-ROM CD CD ROM LSI ROM CD-ROM 3/17 3 http://www.pc-view.net/special/000411/ 4/17 4 http://www.pc-view.net/special/000411/page2.html 5 5/17 6/17 7/17 2PS2 6 8/17 7 9/17 8 10/17

More information

untitled

untitled -1- -2- -4- -5- 20 30 12-6- 8 15 1-7- -8- -9- -10- 40 60-11- -12- 3 4 70 90-13- -14- 2 4 3 5-15- a 3-16- -17- -18- 128 kg 150 200g 100 200g 250 750g 2 1 94 89 89 81 72 390 97 97 83 83 75 97 97 100 86

More information

untitled

untitled The Current State of Local News in Japan Examined through Content Analysis Hiroki Fukasawa 2014 2015 6 11 23TBS 4 1 5 123 Komazawa Journal of Sociology No.48, 2016 2 1 28, 2015b 124 6 2007 Muzak Newszak

More information

EL 9.5m EL -4.5m ,13Cr, 27 (1978) 292 P.64 B ,, ,, 40 (1991) 453 P.58 2-65SUS316 P.31 H.Ishii, et al, The Effects of Heat Treatments on Corrosion Fatigue Properties of 13%

More information

- 1 -

- 1 - 19 21 - 1 - - 2 - - 3 - - 4 - 19 21 21 2224-5 - 19 2007 21 2009 H18 H27 18 27 10 H18 H22 18 22 22 H19 H21 19 21 21-6 - 20 21 19 2,449,254 2,495,506 1.9% 2,603,427 4.3% 1,593,428 1,582,704 0.7% 1,552,160

More information

™·”õ/sec3_p63_84/fiü“eflÅ

™·”õ/sec3_p63_84/fiü“eflÅ Section3 64 1 65 Section 3 1 2 3 4 5 6 7 8 9 10 11 12 13 14 1 Babara E. Ainsworth et al. Med. Sci. Sports. Exevc.1993 66 67 Section 3 1 10 9 8 1 2 3 4 7 6 5 6 7 5 1 2 3 4 68 69 Section 3 2 70 Section 3

More information

nsg02-13/ky045059301600033210

nsg02-13/ky045059301600033210 φ φ φ φ κ κ α α μ μ α α μ χ et al Neurosci. Res. Trpv J Physiol μ μ α α α β in vivo β β β β β β β β in vitro β γ μ δ μδ δ δ α θ α θ α In Biomechanics at Micro- and Nanoscale Levels, Volume I W W v W

More information

(1604)活動火口に形成された火口湖における熱活動モニタリング

(1604)活動火口に形成された火口湖における熱活動モニタリング 25 1604 2. 2 2-2 H24 1 10% H24 21 25 1. 2-3 1.1 2 2011 12 3 2012 3 1 30 WEB 2012 5 6 7 5 1 9 2012 3 3 50 1.2 2012 4 70 10 220 MW 2 500-600 MW 1 1 5 m -9 cm 4 2012 2011 3 2011 12 2011 3 29 580 mg/l 2012

More information

1 2 3 4 5 68g 9g 2g 0.2mg 0.8mg 316kcal 316cal 326kcal 326cal 6 010 3035 15 5355 30 120 20 7 8 9 10 11 () () () 12 1 3 1 5 1 80kcal 20 30 20 30 1 9 7.5 13 7.58.5 910.5 1213.5 11.512.5 14 15 79 23 1520

More information

Florigen in rice Key words Shojiro Tamaki, Ko Shimamoto E-mail : s-tamaki@bs.naist.jp, simamoto@bs.naist.jp URL : http://bsw3.naist.jp/simamoto/simaoto.html 1) Thomas, B., Vince-prue, D.: Photoperiodism

More information

114 17 4 1 1 4 4.1kg 4.1kg 4 1 1979 P G

114 17 4 1 1 4 4.1kg 4.1kg 4 1 1979 P G 113 1 1980 2000 1000 1980 400 1980 2 1 2010 2 24 14:50 16:50 114 17 4 1 1 4 4.1kg 4.1kg 4 1 1979 P G 115 12 2 1 116 17 2 85 PH 7 60 PH 8 117 118 17 119 3 3 1 1 2 RD 3 1 R&D RD 120 17 6-7 RD 2 RD 30 60

More information

1.医薬品開発forWeb.ppt

1.医薬品開発forWeb.ppt 1 4/15 4/22 CC/TBDD(CADD) 5/6-1 1 5/6-2 1 4/15 BO:17-2-1-1 BO:17-2-1-1 Drug Discovery based on Genome (Information) Combinatorial Chemistry Random screening Lead Optimization target validation Target Validation

More information

234 50cm

234 50cm 234 50cm () 1 10 2 3 4 1 5 6 2 2 1 7 ( ー ) っ ー っ 8 1 2 10 10 2m 4m 6m 15m 457-2472 585-1154 9 10 2 60 2 100 RC SRC 30 80 500 1 500 500 ) 10 B b A 2 A B 2m 457-2473 585-1154 11 20m a 2m 3 3 1m 75cm 120cm

More information

Graminex社の”花粉エキスG63”による前立腺炎への知見

Graminex社の”花粉エキスG63”による前立腺炎への知見 Graminex G63 IPSS Graminex Graminex G60 GFX 1 3 1 mg 62.5mg 66.1 5.7 17 29 Graminex G63 ED ED ED ED G63 IIEF5 G Graminex Graminex G60 GFX 1 3 1 mg 62.5mg 9 69.2 3 23.1 1 7.7 1 ED 1 1 2005.10.14 Graminex

More information

iii iv v vi 21 A B A B C C 1 1 2 3 4 5 6 1 2 3 4 5 6 7 8 9 10 11 19 22 30 39 43 48 54 60 65 74 77 84 87 89 95 101 12 20 23 31 40 44 49 55 61 66 75 78 85 88 90 96 102 13 21 24 32 41 45 50 56 62 67 76 79

More information

橡35tsukiashi.PDF

橡35tsukiashi.PDF 1 1.1 1. 1 1.3.1..3. 3.1 3. 3.3 3. 3.5 1987 00 3 006 7 10 11 1 a. NPI.. 100 10 130 106 [ ] 5 NPI NPI 1986 1990 1 3 NPI 5 NPI 15 NPI A. B. C. D. E. F. G. A. B C. D. E. F. G. A. B. C. D. E. F. G. 1.. 3..

More information

プラズマ・核融合学会

プラズマ・核融合学会 1. Philosophy of Radiological Protection and Radiation Hazard Protection Law 1) Oita University of Nursing and Health Sciences, Oita, OITA 870-1201, Japan 2) National Institute for Fusion Science, Toki,

More information

Wn PCB PCB PCB YES NO SMW YES NO YES NO ALC PC PCGRCPC PC FR PC PC PC ALC PC ALC PCB PCB PCB PCB PCB PCB PCB PCB PCB PCBPCB PCB PCB PCBPCB

More information

untitled

untitled 2007 12 1 871146 IF 1998 9 350mg 250mg 100mg 10mg 10mg Sodium Salicylate Sulpyrine Hydrate Caffeine Hydrate Allobarbital Procaine Hydrochloride 2007 8 31 2007 12 21 1955 2 FAX TEL FAX IF 2007 12 6 IF 1

More information

用法 用量 発作性夜間ヘモグロビン尿症における溶血抑制 mg mg mg mg kg 30kg 40kg 20kg 30kg 10kg 20kg 5kg 10kg 1900mg mg mg mg

用法 用量 発作性夜間ヘモグロビン尿症における溶血抑制 mg mg mg mg kg 30kg 40kg 20kg 30kg 10kg 20kg 5kg 10kg 1900mg mg mg mg C EculizumabGenetical Recombination AMX 警告 1 2 禁忌 ( 次の患者には投与しないこと ) 1 2 組成 性状 ml mg mg mg mg mg ph ph mgml 効能 効果 発作性夜間ヘモグロビン尿症における溶血抑制 < 効能 効果に関連する使用上の注意 > 共通 1C5 C5b-9 b 発作性夜間ヘモグロビン尿症における溶血抑制 1 2 3 4

More information

untitled

untitled 28 20 1 31 4 2 25 1 IgG IgA IgM IgE IgM 2 60 80 70 60 60 40 20 80 35 45 kg 150cc 100 120cc 100cc 30 40cc 7,000g 500cc 120cc 120 5=600cc 600g 30 2,100cc 1,000cc 3 4 14 5 6 7 8 9 10 11 12 SIDS SIDS SIDS

More information

3 5 A06 AS2306 AS2406 AD2406 AD3406 ADE / / ! 8!

3 5 A06 AS2306 AS2406 AD2406 AD3406 ADE / / ! 8! 35 A06 AS2306 AS2406 AD2406 AD3406 ADE3406 3 3 2 2 3 2-1 / / 2306 2406 2406 3406 3406! 8! 4 220 018 11 560 011 1 600 600 600 360 360 0012 0013 0012 0015 0015 13 85 37 32 250 02 125 200110220 10 5060 240

More information

プラズマ・核融合学会誌

プラズマ・核融合学会誌 5. Validation and Application of a Numerical Tool for Lifetime Evaluation of Ion Thruster s Ion Optics Japan Aerospace Exploration Agency, Sagamihara, KANAGAWA 252-5210, Japan μ10pm author s e-mail: watanabe.hiroki@jaxa.jp

More information

<8EAD8E99938781408C9A90DD2E786C73>

<8EAD8E99938781408C9A90DD2E786C73> (1) ()(1) (1) ()(1) () ()(1) ()(26-5) ()(26-6) ()(2) () (27-1) (27-2) (27-3) (27-1) (27-1) (27-2) 24 1 1.25 1 2 24 1 (2.8)S 1F 370 (1.2) (1.25 ) 1F 202 3,, 24 1 24 1 13 (,) (2.8)S 1F 370 (1.25 )RC 1F 320

More information

外国語教育センタージャーナル第9号

外国語教育センタージャーナル第9号 1. 1 35 45 2. 1 2 2 2013 5 1 31 2 40 3 37 4 40 2 17 2 5 165 148 9 4 4 4 3 1 Dörnyei(2001) 2 3 2 119 2 60 2 4 1 1 30 1 2 2 6 4 3 3.1 5 3 5 90 4 5 120 6 PPT K-POP 3.2 10 40 7 7 2005 10 8 5 9 6 7 3 5 8 9

More information

医薬品リスク管理計画書

医薬品リスク管理計画書 2.5 mg 3.75 mg 5 mg 20mg RMP 2.5 mg 3.75 mg 5 mg 20mg 87339 28 6 1.1 4 8 10 5 8 10 5 TTP 9 梗 6 TIA 11 6 1.2 11 CABG 12 12 13 13 15 2.5mg 15 2. 16 3. 16 4. 19 19 19 18 RMP 28 6 3 5 1 27 8 25 26 3 24 87339

More information

1950 1970 1990 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 6,788 7,123 5,384 4,915 4,908 4,927 4,895 4,919 4,936 4,927 4,897 5,010 5,008 1,456 1

1950 1970 1990 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 6,788 7,123 5,384 4,915 4,908 4,927 4,895 4,919 4,936 4,927 4,897 5,010 5,008 1,456 1 1950 1970 1990 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 6,788 7,123 5,384 4,915 4,908 4,927 4,895 4,919 4,936 4,927 4,897 5,010 5,008 1,456 1,616 927 824 826 821 813 808 802 803 801 808 806 18,483

More information

/ / LIN X*** Y*** Z*** A*** F***; END; " " " " TB V10.jtd-2

/ / LIN X*** Y*** Z*** A*** F***; END;     TB V10.jtd-2 2011/05/24 1 Y Y TB04-2394-V10.jtd-1 / / 1 1 2 3 4 5 6 6 6 5 1 2 4 5 1 1 1 4 3 4 3 1 2 1 2 LIN X*** Y*** Z*** A*** F***; END; " " " " TB04-2394-V10.jtd-2 1 LIN X1400 Y-1400 Z12 A0 F3000; LIN X0 Y-4000

More information